Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.…
Phase 2 Psoriasis Results Could Be A Big Moment For Oruka Therapeutics Stock (ORKA)
Oruka Therapeutics (NASDAQ: ORKA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 68 employees.
The shares were at 95.81 USD on 20 November 2026, up 238.8% over 52 weeks. Its 52-week range is 25.23 USD to 115.51 USD: the price is 17.1% below the high and 279.7% above the low.
Its market capitalisation is 6.50B USD.
Oruka Therapeutics reports return on equity of -22.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 917.34M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 156.17 USD is 63.0% above the current price. The next earnings report is expected on 11 March 2027.